BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--BIOTRONIK, the pioneer in wireless remote monitoring technologies for patients with implantable cardiac pacemakers and defibrillators, announced today the FDA approval to begin an international, prospective, randomized, controlled clinical trial to investigate the use of Cardiac Resynchronization Therapy (CRT) in heart failure (HF) patients with left ventricular systolic dysfunction.
